ArticleHaematologica2026

Outcomes of real-world complete responders after fixed duration glofitamab in relapsed/refractory large B-cell lymphoma.

Evgenii Shumilov et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.